The traditional diagnostic approach of lung cancer involves tissue biopsy for histological confirmation, followed by biomarker testing using various assays including immunohistochemical staining for ALK fusion and BRAF V600E mutation [2,3], PCR for EGFR [4,5], and fluorescence in situ hybridization for ROS1 fusion [6,7,8] on residual samples. This evidence concerns the gene EGFR and lung cancer.